AtriCure introduces new EnCompass clamp and publishes hybrid AF therapy guide
AtriCure announced the first worldwide use of the Isolator® Synergy™ EnCompass® clamp in Montreal hospitals and unveiled a Hybrid Best Practices Guide developed by 25 authors from 10 countries
Key points
- The company said surgeons at Hôpital du Sacré‑Coeur‑de‑Montréal and Fondation de l'Hôpital du Sacré‑Coeur‑de‑Montréal completed the first case with the Isolator® Synergy™ EnCompass® clamp on Oct.
- The guide targets patients with long‑standing persistent atrial fibrillation (LSPAF) for whom hybrid therapy is considered a durable treatment
- The clamp delivers adaptive RF energy in real time, which the company says reduces guesswork when creating lesions, and the two sizes increase procedural flexibility
What happened
The company said surgeons at Hôpital du Sacré‑Coeur‑de‑Montréal and Fondation de l'Hôpital du Sacré‑Coeur‑de‑Montréal completed the first case with the Isolator® Synergy™ EnCompass® clamp on Oct. 14
The clamp provides real‑time, patient‑specific adaptive radiofrequency (RF) energy, ensuring consistent lesion quality in every case
It is offered in two versions – standard and long – enabling sizing to match patient anatomy
At the same time, AtriCure released a Hybrid Best Practices Guide with contributions from 25 authors in 10 countries to standardize combined epicardial‑endocardial hybrid AF therapy
Who it matters to
The guide targets patients with long‑standing persistent atrial fibrillation (LSPAF) for whom hybrid therapy is considered a durable treatment
Proof of efficacy
The clamp delivers adaptive RF energy in real time, which the company says reduces guesswork when creating lesions, and the two sizes increase procedural flexibility
The guide consolidates international experience to unify approaches, potentially improving treatment consistency
Next step
Further use of the clamp at other centers and adoption of the guide’s recommendations will determine its impact on AF therapy; the company has not announced additional regulatory filings
Original sources
- LinkedIn-USA,ASIA,CANADA-urn:li:ugcPost:7515788900230037504
- Twitter-2110385657583403327
- LinkedIn-USA,ASIA,CANADA-urn:li:share:7516151118033338369
- Twitter-2110464430970388765
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow AtriCure
A notification in your browser or on your phone when we publish about AtriCure. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
